Novartis’s Tekturna found to be effective against high blood pressure
Results from the Ageless study showed that Rasilez/Tekturna provides an additional reduction in systolic blood pressure of 2.3mmHg in patients aged 65 and over compared to the angiotensin-converting
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.